{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:45:05Z","timestamp":1791405905422,"version":"4.3.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,3,7]],"date-time":"2006-03-07T00:00:00Z","timestamp":1141689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1007\/s00401-006-0042-3","type":"journal-article","created":{"date-parts":[[2006,3,6]],"date-time":"2006-03-06T10:38:04Z","timestamp":1141641484000},"page":"436-443","source":"Crossref","is-referenced-by-count":31,"title":["Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt\u2013Jakob disease"],"prefix":"10.1007","volume":"111","author":[{"given":"Silke","family":"Vogelgesang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Glatzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lary C.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heyo K.","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Aguzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf W.","family":"Warzok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,3,7]]},"reference":[{"key":"42_CR1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/0470846356.ch4","volume":"243","author":"NJ Abbott","year":"2002","unstructured":"Abbott NJ, Khan EU, Rollinson CM, Reichel A, Janigro D, Dombrowski SM, Dobbie MS, Begley DJ (2002) Drug resistance in epilepsy: the role of the blood-brain barrier. Novartis Found Symp 243:38\u201347","journal-title":"Novartis Found Symp"},{"key":"42_CR2","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1126\/science.1087348","volume":"302","author":"A Aguzzi","year":"2003","unstructured":"Aguzzi A, Haass C (2003) Games played by rogue proteins in prion disorders and Alzheimer\u2019s disease. Science 302:814\u2013818","journal-title":"Science"},{"key":"42_CR3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0304-3940(00)01725-0","volume":"298","author":"RA Armstrong","year":"2001","unstructured":"Armstrong RA, Lantos PL, Cairns NJ (2001) The spatial patterns of prion protein deposits in Creutzfeldt\u2013Jakob disease: comparison with beta-amyloid deposits in Alzheimer\u2019s disease. Neurosci Lett 298:53\u201356","journal-title":"Neurosci Lett"},{"key":"42_CR4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.molimm.2004.07.005","volume":"42","author":"GS Begley","year":"2005","unstructured":"Begley GS, Horvath AR, Taylor JC, Higgins CF (2005) Cytoplasmic domains of the transporter associated with antigen processing and P-glycoprotein interact with subunits of the proteasome. Mol Immunol 42:137\u2013141","journal-title":"Mol Immunol"},{"key":"42_CR5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/bmb\/66.1.121","volume":"66","author":"H Budka","year":"2003","unstructured":"Budka H (2003) Neuropathology of prion diseases. Br Med Bull 66:121\u2013130","journal-title":"Br Med Bull"},{"key":"42_CR6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(97)02073-4","volume":"350","author":"RW Carrell","year":"1997","unstructured":"Carrell RW, Lomas DA (1997) Conformational disease. Lancet 350:134\u2013138","journal-title":"Lancet"},{"key":"42_CR7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1067\/mcp.2001.114164","volume":"69","author":"I Cascorbi","year":"2001","unstructured":"Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I (2001) Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169\u2013174","journal-title":"Clin Pharmacol Ther"},{"key":"42_CR8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1212\/WNL.51.2.548","volume":"51","author":"J Chapman","year":"1998","unstructured":"Chapman J, Cervenakova L, Petersen RB, Lee HS, Estupinan J, Richardson S, Vnencak-Jones CL, Gajdusek DC, Korczyn AD, Brown P, Goldfarb LG (1998) APOE in non-Alzheimer amyloidoses: transmissible spongiform encephalopathies. Neurology 51:548\u2013553","journal-title":"Neurology"},{"issue":"Suppl 4","key":"42_CR9","doi-asserted-by":"crossref","first-page":"16419","DOI":"10.1073\/pnas.212527999","volume":"99","author":"F Chiti","year":"2002","unstructured":"Chiti F, Calamai M, Taddei N, Stefani M, Ramponi G, Dobson CM (2002) Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. Proc Natl Acad Sci USA 99(Suppl 4):16419\u201316426","journal-title":"Proc Natl Acad Sci USA"},{"key":"42_CR10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0896-6273(03)00606-8","volume":"40","author":"A Ciechanover","year":"2003","unstructured":"Ciechanover A, Brundin P (2003) The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40:427\u2013446","journal-title":"Neuron"},{"key":"42_CR11","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1172\/JCI25247","volume":"115","author":"JR Cirrito","year":"2005","unstructured":"Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115:3285\u20133290","journal-title":"J Clin Invest"},{"key":"42_CR12","first-page":"113","volume-title":"The dementias","author":"J Collinge","year":"1998","unstructured":"Collinge J (1998) Human prion diseases: aetiology and clinical features. In: Growdon JH, Rossor M, Newton MA (eds) The dementias. Butterworth-Heinemann, Oxford, pp 113\u2013148"},{"issue":"Suppl 1","key":"42_CR13","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1161\/01.STR.0000143452.85382.d1","volume":"35","author":"R Deane","year":"2004","unstructured":"Deane R, Wu Z, Zlokovic BV (2004) RAGE (yin) versus LRP (yang) balance regulates alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 35(Suppl 1):2628\u20132631","journal-title":"Stroke"},{"key":"42_CR14","first-page":"785","volume":"146","author":"SJ DeArmond","year":"1995","unstructured":"DeArmond SJ, Prusiner SB (1995) Etiology and pathogenesis of prion diseases. Am J Pathol 146:785\u2013811","journal-title":"Am J Pathol"},{"key":"42_CR15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1537-1891(02)00201-X","volume":"38","author":"M Demeule","year":"2002","unstructured":"Demeule M, Regina A, Jodoin J, Laplante A, Dagenais C, Berthelet F, Moghrabi A, Beliveau R (2002) Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol 38:339\u2013348","journal-title":"Vascul Pharmacol"},{"key":"42_CR16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00008571-200305000-00004","volume":"13","author":"M Drozdzik","year":"2003","unstructured":"Drozdzik M, Bialecka M, Mysliwiec K, Honczarenko K, Stankiewicz J, Sych Z (2003) Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson\u2019s disease. Pharmacogenetics 13:259\u2013263","journal-title":"Pharmacogenetics"},{"key":"42_CR17","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0002-9440(10)64794-3","volume":"157","author":"MF Fromm","year":"2000","unstructured":"Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum M, Siegmund W, Schrenk D (2000) The effect of rifampin treatment on intestinal expression of human MRP transporters. Am J Pathol 157:1575\u20131580","journal-title":"Am J Pathol"},{"key":"42_CR18","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tips.2004.06.002","volume":"25","author":"MF Fromm","year":"2004","unstructured":"Fromm MF (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25:423\u2013429","journal-title":"Trends Pharmacol Sci"},{"key":"42_CR19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1097\/00008571-200210000-00004","volume":"12","author":"T Furuno","year":"2002","unstructured":"Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, Martignoni E, Schaeffeler E, Eichelbaum M, Schwab M, Zanger UM (2002) Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson\u2019s disease. Pharmacogenetics 12:529\u2013534","journal-title":"Pharmacogenetics"},{"key":"42_CR20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0140-6736(02)09384-4","volume":"360","author":"M Glatzel","year":"2002","unstructured":"Glatzel M, Rogivue C, Ghani A, Streffer JR, Amsler L, Aguzzi A (2002) Incidence of Creutzfeldt\u2013Jakob disease in Switzerland. Lancet 360:139\u2014141","journal-title":"Lancet"},{"key":"42_CR21","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s004010050870","volume":"96","author":"JA Hainfellner","year":"1998","unstructured":"Hainfellner JA, Wanschitz J, Jellinger K, Liberski PP, Gullotta F, Budka H (1998) Coexistence of Alzheimer-type neuropathology in Creutzfeldt\u2013Jakob disease. Acta Neuropathol 96:116\u2013122","journal-title":"Acta Neuropathol"},{"key":"42_CR22","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1042\/BST0330578","volume":"33","author":"J Hardy","year":"2005","unstructured":"Hardy J (2005) Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: permissive templating as a general mechanism underlying neurodegeneration. Biochem Soc Trans 33:578\u2013581","journal-title":"Biochem Soc Trans"},{"key":"42_CR23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.0306-5251.2001.01516.x","volume":"53","author":"M Hennessy","year":"2002","unstructured":"Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, Mulcahy F, Feely J (2002) St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 53:75\u201382","journal-title":"Br J Clin Pharmacol"},{"key":"42_CR24","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473\u20133478","journal-title":"Proc Natl Acad Sci USA"},{"key":"42_CR25","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0168-9525(98)01559-5","volume":"14","author":"A Kakizuka","year":"1998","unstructured":"Kakizuka A (1998) Protein precipitation: a common etiology in neurodegenerative disorders? Trends Genet 14:396\u2013402","journal-title":"Trends Genet"},{"key":"42_CR26","doi-asserted-by":"crossref","first-page":"9989","DOI":"10.1073\/pnas.96.18.9989","volume":"96","author":"EH Koo","year":"1999","unstructured":"Koo EH, Lansbury PT Jr, Kelly JW (1999) Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc Natl Acad Sci USA 96:9989\u20139990","journal-title":"Proc Natl Acad Sci USA"},{"key":"42_CR27","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0531-5565(01)00219-4","volume":"37","author":"GG Kovacs","year":"2002","unstructured":"Kovacs GG, Budka H (2002) Aging, the brain and human prion disease. Exp Gerontol 37:603\u2013605","journal-title":"Exp Gerontol"},{"key":"42_CR28","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1046\/j.1471-4159.2001.00113.x","volume":"76","author":"FC Lam","year":"2001","unstructured":"Lam FC, Liu R, Lu P, Shapiro AB, Renoir JM, Sharom FJ, Reiner PB (2001) beta-Amyloid efflux mediated by P-glycoprotein. J Neurochem 76:1121\u20131128","journal-title":"J Neurochem"},{"key":"42_CR29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0014-4886(02)00060-2","volume":"180","author":"M Lopez Salon","year":"2003","unstructured":"Lopez Salon M, Pasquini L, Besio Moreno M, Pasquini JM, Soto E (2003) Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. Exp Neurol 180:131\u2013143","journal-title":"Exp Neurol"},{"key":"42_CR30","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1126\/science.1073619","volume":"298","author":"J Ma","year":"2002","unstructured":"Ma J, Lindquist S (2002) Conversion of PrP to a self-perpetuating PrPSc-like conformation in the cytosol. Science 298:1785\u20131788","journal-title":"Science"},{"key":"42_CR31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.neuron.2004.07.003","volume":"43","author":"S Oddo","year":"2004","unstructured":"Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43:321\u2013332","journal-title":"Neuron"},{"key":"42_CR32","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1212\/WNL.54.5.1099","volume":"54","author":"M Otto","year":"2000","unstructured":"Otto M, Esselmann H, Schulz-Shaeffer W, Neumann M, Schroter A, Ratzka P, Cepek L, Zerr I, Steinacker P, Windl O, Kornhuber J, Kretzschmar HA, Poser S, Wiltfang J (2000) Decreased beta-amyloid1\u201342 in cerebrospinal fluid of patients with Creutzfeldt\u2013Jakob disease. Neurology 54:1099\u20131102","journal-title":"Neurology"},{"key":"42_CR33","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/1531-8249(199908)46:2<224::AID-ANA12>3.0.CO;2-W","volume":"46","author":"P Parchi","year":"1999","unstructured":"Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, Zerr I, Budka H, Kopp N, Piccardo P, Poser S, Rojiani A, Streichemberger N, Julien J, Vital C, Ghetti B, Gambetti P, Kretzschmar H (1999) Classification of sporadic Creutzfeldt\u2013Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol 46:224\u2013233","journal-title":"Ann Neurol"},{"key":"42_CR34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/07853890410031948","volume":"36","author":"L Petrucelli","year":"2004","unstructured":"Petrucelli L, Dawson TM (2004) Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system. Ann Med 36:315\u2013320","journal-title":"Ann Med"},{"key":"42_CR35","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1038\/sj.emboj.7600462","volume":"23","author":"NS Rane","year":"2004","unstructured":"Rane NS, Yonkovich JL, Hegde RS (2004) Protection from cytosolic prion protein toxicity by modulation of protein translocation. EMBO J 23:4550\u20134559","journal-title":"EMBO J"},{"key":"42_CR36","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/jnen\/62.9.885","volume":"62","author":"T Revesz","year":"2003","unstructured":"Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, Holton JL (2003) Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 62:885\u2013898","journal-title":"J Neuropathol Exp Neurol"},{"key":"42_CR37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","volume":"55","author":"AH Schinkel","year":"2003","unstructured":"Schinkel AH, Jonker JW (2003) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55:3\u201329","journal-title":"Adv Drug Deliv Rev"},{"key":"42_CR38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev.pharmtox.43.100901.140233","volume":"43","author":"M Schwab","year":"2003","unstructured":"Schwab M, Eichelbaum M, Fromm MF (2003) Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43:285\u2013307","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"42_CR39","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1172\/JCI10498","volume":"106","author":"M Shibata","year":"2000","unstructured":"Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV. (2000) Clearance of Alzheimer\u2019s amyloid-ss(1\u201340) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106:1489\u20131499","journal-title":"J Clin Invest"},{"key":"42_CR40","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1073\/pnas.95.12.7024","volume":"95","author":"MJ Smyth","year":"1998","unstructured":"Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW (1998) The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95:7024\u20137029","journal-title":"Proc Natl Acad Sci USA"},{"key":"42_CR41","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.cdd.4401440","volume":"11","author":"KM Tainton","year":"2004","unstructured":"Tainton KM, Smyth MJ, Jackson JT, Tanner JE, Cerruti L, Jane SM, Darcy PK, Johnstone RW (2004) Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ 11:1028\u20131037","journal-title":"Cell Death Differ"},{"key":"42_CR42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1602\/neurorx.2.1.63","volume":"2","author":"T Terasaki","year":"2005","unstructured":"Terasaki T, Ohtsuki S (2005) Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: an overview of biology and methodology. NeuroRx 2:63\u201372","journal-title":"NeuroRx"},{"key":"42_CR43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00401-004-0953-9","volume":"109","author":"U Unterberger","year":"2005","unstructured":"Unterberger U, Voigtlander T, Budka H (2005) Pathogenesis of prion diseases. Acta Neuropathol 109:32\u201348","journal-title":"Acta Neuropathol"},{"key":"42_CR44","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00008571-200210000-00005","volume":"12","author":"S Vogelgesang","year":"2002","unstructured":"Vogelgesang S, Cascorbi I, Schroeder E, Pahnke J, Kroemer HK, Siegmund W, Kunert-Keil C, Walker LC, Warzok RW (2002) Deposition of Alzheimer\u2019s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 12:535\u2013541","journal-title":"Pharmacogenetics"},{"key":"42_CR45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2174\/1567205043332225","volume":"1","author":"S Vogelgesang","year":"2004","unstructured":"Vogelgesang S, Warzok RW, Cascorbi I, Kunert-Keil C, Schroeder E, Kroemer HK, Siegmund W, Walker LC, Pahnke J (2004) The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer\u2019s disease. Curr Alzheimer Res 1:121\u2013125","journal-title":"Curr Alzheimer Res"},{"key":"42_CR46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1385\/MN:21:1-2:083","volume":"21","author":"LC Walker","year":"2000","unstructured":"Walker LC, LeVine H (2000) The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly. Mol Neurobiol 21:83\u201395","journal-title":"Mol Neurobiol"},{"key":"42_CR47","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s004010051190","volume":"100","author":"LC Walker","year":"2000","unstructured":"Walker LC, Pahnke J, Madauss M, Vogelgesang S, Pahnke A, Herbst EW, Stausske D, Walther R, Kessler C, Warzok RW (2000) Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly. Acta Neuropathol 100:36\u201342","journal-title":"Acta Neuropathol"},{"key":"42_CR48","first-page":"782","volume":"3","author":"LC Walker","year":"2002","unstructured":"Walker LC, LeVine H III (2002) Proteopathy: the next therapeutic frontier? Curr Opin Investig Drugs 3:782\u2013787","journal-title":"Curr Opin Investig Drugs"},{"key":"42_CR49","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00002093-199803000-00005","volume":"12","author":"RW Warzok","year":"1998","unstructured":"Warzok RW, Kessler C, Apel G, Schwarz A, Egensperger R, Schreiber D, Herbst EW, Wolf E, Walther R, Walker LC (1998) Apolipoprotein E4 promotes incipient Alzheimer pathology in the elderly. Alzheimer Dis Assoc Disord 12:33\u201339","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"42_CR50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ana.10661","volume":"54","author":"J Wiltfang","year":"2003","unstructured":"Wiltfang J, Esselmann H, Smirnov A, Bibl M, Cepek L, Steinacker P, Mollenhauer B, Buerger K, Hampel H, Paul S, Neumann M, Maler M, Zerr I, Kornhuber J, Kretzschmar HA, Poser S, Otto M (2003) Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt\u2013Jakob disease. Ann Neurol 54:263\u2013267","journal-title":"Ann Neurol"},{"key":"42_CR51","first-page":"952","volume":"59","author":"ZY Yang","year":"2004","unstructured":"Yang ZY, Liu GQ (2004) Effect of P-glycoprotein inhibitor combinations on drug efflux from rat brain microvessel endothelial cells. Pharmazie 59:952\u2013956","journal-title":"Pharmazie"},{"key":"42_CR52","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1093\/emboj\/20.19.5383","volume":"20","author":"Y Yedidia","year":"2001","unstructured":"Yedidia Y, Horonchik L, Tzaban S, Yanai A, Taraboulos A (2001) Proteasomes and ubiquitin are involved in the turnover of the wild-type prion protein. EMBO J 20:5383\u20135391","journal-title":"EMBO J"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-006-0042-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00401-006-0042-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-006-0042-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T01:06:08Z","timestamp":1706922368000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00401-006-0042-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,7]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["42"],"URL":"https:\/\/doi.org\/10.1007\/s00401-006-0042-3","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,7]]}}}